Publications by authors named "David Miklos"

Claim this Profile
N
NKTR-255 enhances complete response following CD19 CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma.
Sairah Ahmed, John DiPersio, James Essell, Catherine Diefenbach, Miguel-Angel Perales, David Miklos

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Impact of Anti-CD38 Monoclonal Antibody Therapy on Stem-Cell Mobilization Yields in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Referred From Community and Academic Oncology Practices: Single Center, Real World Data 2021-2024.
Dilek Uzun, Jeddeo Michael Paul, Alexandria Jensen, John Tamaresis, Walter Domingo, David Miklos

Transplant Cell Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and Cytokine Features of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.
Hrishikesh K Srinagesh, Anne Marijn Kramer, John H Baird, Agnes Reschke, Bita Sahaf, David B Miklos

Blood Cancer Discov· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment kinetics and local response during and after bridging radiotherapy prior to CAR-T cell therapy for lymphomas.
Daniella Klebaner, Natalie J Park, Mallika Marar, Matthew Frank, Susan M Hiniker, David Miklos

Leuk Lymphoma· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recommendations for Defining Chimeric Antigen Receptor T-Cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Phase CAR T Therapy Studies.
Frederick L Locke, Sarah Nikiforow, Matthew J Frigault, David G Maloney, Marco Davila, David B Miklos

Transplant Cell Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Axicabtagene Ciloleucel in Combination With Atezolizumab in Patients With Refractory Diffuse Large B-cell Lymphoma: The Phase 1/2 ZUMA-6 Trial.
Caron A Jacobson, Jason R Westin, David B Miklos, Alex F Herrera, Jerome Ritz

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term Follow-up of Gastrointestinal CAR T-cell Lymphoma: Homing, Clonal Expansion, and Response to Cyclosporine.
Hitomi Hosoya, Armando N Bastidas Torres, Sebastian Fernandez-Pol, John Mark Gubatan, Safa Najidh, David B Miklos

Blood· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Who Is Eligible for Chimeric Antigen Receptor T Cell Therapy? Expert Perspectives on Overcoming Referral Barriers.
Mazyar Shadman, Sairah Ahmed, Michael T Byrne, Julio C Chavez, Manali Kamdar, David B Miklos

Transplant Cell Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting.
Bradley D Hunter, Matthew Lunning, Mazyar Shadman, Sairah Ahmed, Jeremy S Abramson, David B Miklos

Transplant Cell Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias.
Mark P Hamilton, Nick Phillips, Troy Noordenbos, Jan Boegeholz, Takeshi Sugio, David B Miklos

Res Sq· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fatal recurrence of IEC-HS after autologous stem cell boost in patients receiving BCMA-CAR T-cell therapy.
Snegha Ananth, Nancy Eunice Torres, Bita Sahaf, Lekha Mikkilineni, Sebastian Fernandez-Pol, David Miklos

Blood Adv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel.
Frederick L Locke, Tanya Siddiqi, Caron A Jacobson, Sarah Nikiforow, Sairah Ahmed, David B Miklos

Blood Adv· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Donor regulatory T-cell therapy to prevent graft-versus-host disease.
Everett H Meyer, Anna Pavlova, Alejandro Villar-Prados, Cameron Bader, Bryan Xie, David Miklos

Blood· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies.
Frederick L Locke, Javier L Munoz, Michael T Tees, Lazaros J Lekakis, Sven de Vos, David B Miklos

J Clin Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL.
Yi-Jiun Su, Anne Marijn Kramer, Mark P Hamilton, Neha Agarwal, Hrishikesh K Srinagesh, David B Miklos

Cancer Discov· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lisocabtagene Maraleucel for Richter's Transformation-A Case Series.
Courtney J Smith, Anmol Goyal, Brian R Smith, Dasom Lee, Alexandria Jensen, David Miklos

EJHaem· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review.
David B Miklos, Peter A Riedell, Alex Bokun, Julio C Chavez, Stephen J Schuster

Target Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma.
Hitomi Hosoya, Mia Carleton, Kailee Tanaka, Brian Sworder, Shriya Syal, David Miklos

Nat Commun· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma.
Frederick L Locke, Sattva S Neelapu, Nancy L Bartlett, Lazaros J Lekakis, Caron A Jacobson, David B Miklos

Transplant Cell Ther· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia.
Hrishikesh Srinagesh, Clayton Jackson, Parveen Shiraz, Nikeshan Jeyakumar, Mark Hamilton, David Miklos

Blood· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
Michael D Jain, Jay Y Spiegel, Loretta J Nastoupil, John Tamaresis, Armin Ghobadi, David B Miklos

J Clin Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma.
Surbhi Sidana, Andriyana K Bankova, Hitomi Hosoya, Shaji K Kumar, Tyson H Holmes, David B Miklos

Blood Cancer J· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy. Reply.
Mark P Hamilton, David B Miklos, Ash A Alizadeh

N Engl J Med· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma.
Sushma Bharadwaj, Eric Lau, Mark P Hamilton, Anmol Goyal, Hrishi Srinagesh, David Miklos

J Immunother Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.
Matthew J Frank, John H Baird, Anne Marijn Kramer, Hrishikesh K Srinagesh, Shabnum Patel, David B Miklos

Lancet· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis